[New therapeutic possibilities with drugs affecting serotonin receptors].
The past decade has seen important progress in understanding the localization, pharmacology, and function of serotonin (5-HT) receptor subtypes. At least seven subclasses have been shown to exist, and evidence is emerging to suggest further subclassification. Serotonin is involved in numerous physiological processes (e.g. feeding, sleep, pain, sexual behavior, temperature regulation) and pathophysiological ones. Serotonin reuptake blockers have been found effective in the alleviation of depression and attacks of panic, and are at varying stages of clinical evaluation in the treatment of obsessive compulsive disorder, chronic pain, and bulimia nervosa. Selective potent serotonin receptor agonists and antagonists show promise in the treatment of migraine, nausea and vomiting, schizophrenia, anxiety, hypertension, and Raynaud's disease.
Spigset
O
O
Avdelningen för klinisk farmakologi Regionsjukhuset, Umeå.
D000700:Analgesics / Q000494:pharmacology; D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology; D000932:Antiemetics / Q000494:pharmacology; D000959:Antihypertensive Agents / Q000494:pharmacology; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy; D008881:Migraine Disorders / Q000188:drug therapy; D011928:Raynaud Disease / Q000188:drug therapy; D011985:Receptors, Serotonin / Q000187:drug effects*; D012702:Serotonin Antagonists / Q000494:pharmacology*
D000700:Analgesics; D000928:Antidepressive Agents; D000932:Antiemetics; D000959:Antihypertensive Agents; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists
Nye terapeutiske muligheter med legemidler som påvirker serotoninreseptorer.